Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actelion Ltd
Video: Tracleer bosentan Receives EU Approval for Treatment of Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
August 22nd, 2008
Actelion Ltd announced that Tracleer(R) (bosentan), a dual endothelin receptor antagonist, has been approved in the European Union for the treatment of patients with mildly symptomatic pulmonary arterial hypertension (PAH WHO functional class FC II). Since 2002, Tracleer(R) has been approved and available in the European Union for PAH patients with WHO FC III. To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/actelion/34327/ Tracleer(R) is the first PAH treatment ever to be investigated in a clinical study that exclusively enrolled patients with mildly symptomatic WHO FC II. This 185-patient randomized, double-blind,...
Source: Health Business Week (2008-08-22)
|
